3rd European Conference for Clinical Nanomedicine
including CLINAM “University Village” and Foyer Pioneers-Exhibition
May 10 – 12, 2010
This conference is
- The focal meeting point in Europe to get insight into the state of the art in clinical nanomedicine and to learn about the research and latest results in Nanomedicine.
- The place to investigate not only the state of the art of clinical nanomedicine but also the translational pathway towards the practice, the product and the applicability to the benefit of patients.
- The conference with a small foyer exhibition for pioneers and a university village for universities and research institutes, presenting novel approaches, new research projects and initial outcomes of research and experimental results.
- The translational meeting striving to bridge the research side with the applicability of Nanomedicine to the benefit of the patient
- The pathway to best practice for interdisciplinary cooperation in order to achieve translation in Nanomedicine .
Dowload the Conference Programme 2010 How to get to the conference ---> See Programme of past Conferences (2008 / 2009)
REGISTRATION CLINAM-CONFERENCE 2010
APPLICATION FORM “EXHIBITION” AND “UNIVERSITY VILLAGE”
HOTEL RESERVATION AT SWISSÔTEL LE PLAZA AT PARTICIPANTS RAT
Some Topics within the European Conference for Clinical Nanomedicine 2010
The Complexity of HIV Interaction with its Hosts as Revealed at the Nanometric Level Unsolved Problems in Modern Management of Coronary Artery Disease Unsolved Problems in Diabetes Unsolved Problems in Bacterial Infections Unsolved Problems in Lung Disease Unsolved Problems in Dermatology New Biomaterials for Nanodevices Construction Using Self-Assembled Nanomaterials to Inhibit the Formation of Progress - toward Phase I Human Trials Using a PAMAM Dendrimer Based MRI Contrast Agent for Lymphatic Imaging Nano-Packaging of siRNA: Rationale and First Clinical Experience Immunostimulatory Nano-particles for the Causal Treatment of Allergic Rhinitis: Results from a Phase IIb Study in 300 Patients Suffering from House Dust Allergy Clinical investigation of DermaVir Nanomedicine in HIV-Infected Patients Should the Peripheral Endocannabinoid System be Targeted for the Treatment of the Metabolic Cellular Binding & Uptake of Nano-Objects Enzymatic Degradation of Nanoobjects Intracellular Handling, Trafficking and Breakdown of Nanoobjects Biologic Pathways as Target of Nanodrugs – Targeting Cancer-Stem Cells Without Harming Normal Stem Cells Cancer Vascularisation and Lymphatics – the Fundamental Access Routes for Targeted Therapies Uptake and Elimination Pathways of Nanoparticles Targeted Nanomedicines: Importance of Size, Ligands and EPR Drug Targeting – Quantitative and Qualitative Advantages of Nanodrugs to Conventional Therapy and Monoclonal Antibodies - a Review of Preclinical Evidence Advanced Functionality (siRNA, Photodynamic Therapy, Artificial Organelles Nanoparticles in Personalised Medicine - Prognosis and Prediction Overview on Molecular ligand- and target-systems in cancer Cancer Biomarkers – the Prospect of Nano-arrays for Cancer Proteomics Lab-on-chip for Nucleic Acid and Protein Cancer Biomarkers Detection of Circulating Cancer Cells Nanomedical MR imaging for Cancer and Other Disease – Clinical / PreclinicalNano-medical fluorescence imaging – clinical / preclinical Nanoparticles for Nuclear Medicine: Advantages in PET, SPECT, Radiotherapy Abolishing Systemic Toxicity by Nano-formulation of Drugs Expected and Unexpected Side Effects of Nanodrugs Toxicokinetic Profile of Hard and Soft Nanoparticles Clinical Application of Nano-liposomal drugs for Cancer: Proven Advantages and Open Questions Thermotherapy with Magnetic Nanoparticles: Survival Benefit for Glioblastoma multiforme Patients Tumor-targeting Nanodelivery Platform – New Trials and Results Selected Nanoparticles in Cancer - What has been proven clinically and what is the clinical evidence from established nanodrugs? Visual single Cell Proteomics with Microfluidics: Vision and Preliminary Results Chemotherapy with Magnetic Nanoparticles – an Innovative Method for Local Cancer Treatment The Nanostructure of Human Teeth: Biologically Inspired Dental Treatments Unsolved Problems in Malaria Unsolved Problems in Hereditary Cance Unsolved Problems in Inflammation in Intensive Care Medicine Blood Brain Barrier / Neurology The Unsolved Problem of Targeted Therapy to the Brain – How to Measure efficiency The Portfolio of Presently Nanomedical Targeted Diseases – Principles and practice New Insights on Multifunctional Nano-platform Against Cutaneous Leishmaniasis Nano-Immunology: SPIONS Modulate Dendritic Cell Function and T Cell Responses Multifunctional Use of Paramagnetic Iron Oxide Nanoparticles in Drug and Cell Delivery. Translation Research from Bench to Clinic and its Cross-Reference with Regulatory Hindrance Nanoparticles In Medicine – Regulated Entry and Orchestrated Trafficking, Where is the Risk?” Healthcare Translatability Mean for Nanomedicine– and Whose View Counts? Drug Loaded Immunonanoparticles in the Combat of Cancer Stem Cells - Safety and Efficacy Consideratio Predicting Toxicity and Environmental Relevance of Nanoparticles – a Regulatory Approach Mechanotransduction: Mechanisms of Mechano-Chemical Signal Conversion
...and many further topics
Some of the speakers in Basel on May 10 -12 2010
Federal Councillor Didier Burkhalter, Federal Department of Home Affairs, Berne
Dr. Roland Schenkel, European Commission, Brussels, Director General of the Joint Research Centre (JET) Brussels
Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, University Hospital, Basel
Prof. Dr. med. Luc Montagnier, President and CEO of Nanectis Biotechnology SA. and President of the World Foundation Aids Research and Prevention, UNESCO, Nobel Laureate, Paris
Prof. Frans van de Werf Director of the Clinical Coordinating Centre .and Chair of Cardiovascular Medicine, Leuven
Professor John Pickup MA, BM, BCh, DPhil, FRCPath, Professor of Diabetes and Metabolism Kings College, London
Professor Dr. med. Winfried V. Kern, Department of Medicine, Albert-Ludwigs-University, member of the Executive Committee of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Freiburg
Prof. Dr. med. Nikolaos M. Siafakas, PhD, FRCP, President of European Respiratory Society, Thoracic Medicine, Crete
Prof. Dr. med. Lars E. French, Chairman, Department of Dermatology, Zurich University Hospital, Zürich
Prof. Dr. Patrick Couvreur, Director UMR CNRS 8612, University of Paris-Sud, Chatenay-Malabry
Prof. Dr. Rutledge Ellis-Behnke, Massachusetts Institute of Technology, Cambridge and University of Hong Kong
Prof. Dr. Kazunori Kataoka, Graduate School of Engineering and Division of Clinical Biotechnology Center for Disease Biology and Integrative Medicine Graduate School of Medicine, The University of Tokyo
Prof. Dr. Heinrich Hofmann, EPFL, Laboratoire de Technologie des Poudres, Lausanne
Prof. Dr. Claus-Michael Lehr, Chair for Biopharmaceutics and Pharmaceutical Technology Saarland University, Saarbrücken
Prof. Dr. Marcus Textor, ETH Zurich, BioInterfaceGroup, Laboratory for Surface Science and Technology, Zurich
Prof. Dr. med. Dr. Sc. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest
Prof. Dr. Donald Tomalia, National Dendrimer & Nanotechnology Center, Central Michigan University, Mt. Pleasant
Prof. Dr. Pieter Cullis, Department of Biochemistry and Molecular Biology, University of British Columbia, 2146 Vancouver,
Prof. Dr. Julianna Lisziewicz, CEO of Genetic Immunity, Budapest,
Prof. Dr. med. George Kunos, PhD, Scientific Director, National Institute of Health, Bethesda, Maryland
Dr. med Volker Mailänder, University Clinic of Medicine III, Mainz and the Max Planck Institute for Polymer Science, Mainz
Prof. Dr. Valerian E. Kagan, PhD, DSc, EOH, University of Pittsburg, (USA)
Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director NanoCAN, Odense
Prof. Gerhard Christofori, PhD, Head of the Institute of Biochemistry and Genetics, University of Basel, Basel
Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Dept. of Pharmaceutics, Utrecht University
Prof. Dr. med. Simo Schwartz, Centre d’Investigacions de Bioquimica I Biologia, Hospital Valld’Hebron, Barcelona
Prof. Dr. med. François Berger, Directeur de l’unité Nanomédecine et cerveau“de l’INSERM, Grenoble
Prof. Dr. Klaas Nicolay, Dept. of Biomedical Engineering, Technical University, Eindhoven
Patrick Boisseau, Coordinator of Nano2Life, PM, CEA-Leti, Grenoble
Prof. Dr. Paul Borm Director of Centre of Expertise in Life Sciences,Hogeschool Zuyd, Heerlen andCEO/CSO, of Magnamedics Diagnostics BV, Geleen
Dr. Laurent Lévy, CEO, Nanobiotix, and Co-President of the French Technology Platform on Nanomedicine (FTPN), Paris (F)
Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London
Prof. Dr. med Kathy Pritchard-Jones, President of the European Society for Pediatric Oncology, Sutton
Prof. Dr. med. Alberto Gabizon, Hebrew University, Jerusalem,
Dr. rer. nat. Andreas Jordan, CSO, magForce Nanotechnologie AG, Berlin
Prof. Dr. Esther Chang, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington
Prof. Dr. Bob Sinden, Prof. of Cell Parasite Biology, Head of Infection and Immunity Section and Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London
PD Dr. med. Karl Heinimann, PhD Genetics Department, Children Hospital Basel,
Prof. Dr. med. Didier Payen de la Garanderie, Hospital Lariboisière, Paris
Prof. Dr. Margareta Hammarlund-Udenaes, Ph.D., Professor of Pharmacokinetics and Pharmacodynamics, Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences, Uppsala University
Prof. Dr. Eder Leila Romero, Director NRP, Universidad Nacional de Quilmes, Buenos Aires
Prof. Dr. med. Peter Gehr, Chairman of the Institute of Anatomy, Universityof Berne
Dr. Donald Bruce, Edinethics Ltd., Edinborough, Scotland
Prof. Dr. Rogério Gaspar, Nanomedicine & DDS group, iMed.UL and Faculty of Pharmacy, University of Lisbon
Prof. Dr. Mike Eaton, Head of Biological Chemistry, UCB, Slough
Prof. Dr. Jürgen Borlak, Chair Pharmaco- and Toxicogenomics, Medical School, Director (Fh-ITEM), Hannover
Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials ETH Zürich
Prof. Dr. Giacinto Scoles, SISSA and CBM, Area Science Park, Basovizza, Trieste
Prof. Dr. Werner Arber Nobel Laureate, Basel
Prof, Dr. Jean Marie Lehn, ISIS, Université Louis Pasteur, Strasbourg /Collège de France, Nobel Prize Laureate, (t.b.c)
Prof. Dr. med Matthias Pfisterer, University Hospital Basel
Prof. Dr. Heinrich Rohrer, Nobel Laureate
Dr. Beat Schmid, Head of Preclinical Review, Swissmedic Bern
Dr. Andreas Wallnöfer, Global Head Clinical Research and Exploratory Development, F.Hoffmann-La Roche, AG Basel
Dr. Thomas Lönngren, Executive Director, European Medicines Agency, (former emea), London
...and further speakers
